Arrowhead Pharmaceuticals Inc (ARWR) - Net Assets
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has net assets worth $503.42 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.39 Billion) and total liabilities ($881.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ARWR financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $503.42 Million |
| % of Total Assets | 36.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | 23.14% |
| 10-Year Change | 429.78% |
| Growth Volatility | 185.57 |
Arrowhead Pharmaceuticals Inc - Net Assets Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore ARWR current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual net assets of Arrowhead Pharmaceuticals Inc from 1997 to 2025. For live valuation and market cap data, see Arrowhead Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $503.42 Million | +163.48% |
| 2024-09-30 | $191.06 Million | -33.47% |
| 2023-09-30 | $287.16 Million | -31.36% |
| 2022-09-30 | $418.34 Million | +2.33% |
| 2021-09-30 | $408.82 Million | -11.47% |
| 2020-09-30 | $461.78 Million | +89.23% |
| 2019-09-30 | $244.04 Million | +156.23% |
| 2018-09-30 | $95.24 Million | +17.77% |
| 2017-09-30 | $80.87 Million | -14.90% |
| 2016-09-30 | $95.02 Million | -13.32% |
| 2015-09-30 | $109.62 Million | -33.96% |
| 2014-09-30 | $165.99 Million | +544.98% |
| 2013-09-30 | $25.73 Million | +192.15% |
| 2012-09-30 | $8.81 Million | -29.89% |
| 2011-09-30 | $12.56 Million | +55.53% |
| 2010-09-30 | $8.08 Million | +66.29% |
| 2009-09-30 | $4.86 Million | -60.51% |
| 2008-09-30 | $12.30 Million | -53.50% |
| 2007-09-30 | $26.46 Million | -16.29% |
| 2006-09-30 | $31.61 Million | +12.81% |
| 2005-09-30 | $28.02 Million | +149.57% |
| 2004-09-30 | $11.23 Million | +690.70% |
| 2003-09-30 | $1.42 Million | +191.56% |
| 2002-09-30 | $-1.55 Million | -18.87% |
| 2001-09-30 | $-1.30 Million | -15.53% |
| 2000-09-30 | $-1.13 Million | -13.36% |
| 1999-09-30 | $-996.10K | +62.09% |
| 1998-09-30 | $-2.63 Million | -2.00% |
| 1997-09-30 | $-2.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arrowhead Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 161773993000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $231.00K | 0.05% |
| Other Comprehensive Income | $6.44 Million | 1.38% |
| Other Components | $2.09 Billion | 447.70% |
| Total Equity | $466.05 Million | 100.00% |
Arrowhead Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medibank Private Ltd
AU:MPL
|
$9.20 Billion |
|
China Avionics Systems Co Ltd
SHG:600372
|
$9.21 Billion |
|
Universal Health Services Inc
NYSE:UHS
|
$9.22 Billion |
|
Addtech AB (publ.)
ST:ADDT-B
|
$9.22 Billion |
|
Doosan
KO:000150
|
$9.19 Billion |
|
CITIC Securities Company Limited
F:CI9
|
$9.19 Billion |
|
LG Innotek Co Ltd
KO:011070
|
$9.19 Billion |
|
Taiwan Union Technology
TWO:6274
|
$9.19 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arrowhead Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 185,444,000 to 466,052,000, a change of 280,608,000 (151.3%).
- Net loss of 1,631,000 reduced equity.
- New share issuances of 241,388,000 increased equity.
- Other comprehensive income increased equity by 1,693,000.
- Other factors increased equity by 39,158,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.63 Million | -0.35% |
| Share Issuances | $241.39 Million | +51.79% |
| Other Comprehensive Income | $1.69 Million | +0.36% |
| Other Changes | $39.16 Million | +8.4% |
| Total Change | $- | 151.32% |
Book Value vs Market Value Analysis
This analysis compares Arrowhead Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-09-30 | $-257.62 | $74.81 | x |
| 1998-09-30 | $-262.77 | $74.81 | x |
| 1999-09-30 | $-99.61 | $74.81 | x |
| 2000-09-30 | $-159.91 | $74.81 | x |
| 2001-09-30 | $-182.34 | $74.81 | x |
| 2002-09-30 | $-204.49 | $74.81 | x |
| 2003-09-30 | $175.60 | $74.81 | x |
| 2004-09-30 | $7.10 | $74.81 | x |
| 2005-09-30 | $10.29 | $74.81 | x |
| 2006-09-30 | $9.60 | $74.81 | x |
| 2007-09-30 | $7.33 | $74.81 | x |
| 2008-09-30 | $3.14 | $74.81 | x |
| 2009-09-30 | $1.08 | $74.81 | x |
| 2010-09-30 | $1.41 | $74.81 | x |
| 2011-09-30 | $1.78 | $74.81 | x |
| 2012-09-30 | $0.99 | $74.81 | x |
| 2013-09-30 | $1.15 | $74.81 | x |
| 2014-09-30 | $3.55 | $74.81 | x |
| 2015-09-30 | $1.92 | $74.81 | x |
| 2016-09-30 | $1.57 | $74.81 | x |
| 2017-09-30 | $1.10 | $74.81 | x |
| 2018-09-30 | $1.15 | $74.81 | x |
| 2019-09-30 | $2.48 | $74.81 | x |
| 2020-09-30 | $4.58 | $74.81 | x |
| 2021-09-30 | $3.94 | $74.81 | x |
| 2022-09-30 | $3.78 | $74.81 | x |
| 2023-09-30 | $2.54 | $74.81 | x |
| 2024-09-30 | $1.55 | $74.81 | x |
| 2025-09-30 | $3.48 | $74.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arrowhead Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.20%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 3.11x
- Recent ROE (-0.35%) is above the historical average (-69.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 0.00% | -1115.73% | 0.71x | 0.00x | $-596.92K |
| 1998 | 0.00% | -273.32% | 0.71x | 0.00x | $97.74K |
| 1999 | 0.00% | 1602.80% | 0.45x | 0.00x | $692.61K |
| 2000 | 0.00% | -552.91% | 0.38x | 0.00x | $-24.64K |
| 2001 | 0.00% | -1995.50% | 0.20x | 0.00x | $-55.37K |
| 2002 | 0.00% | -10865.27% | 0.04x | 0.00x | $-91.14K |
| 2003 | -6.71% | 0.00% | 0.00x | 1.07x | $-237.21K |
| 2004 | -26.76% | -1287.86% | 0.02x | 1.26x | $-3.47 Million |
| 2005 | -26.24% | -1160.51% | 0.02x | 1.11x | $-9.47 Million |
| 2006 | -61.94% | -3190.35% | 0.02x | 1.13x | $-22.06 Million |
| 2007 | -113.79% | -2477.70% | 0.04x | 1.13x | $-32.56 Million |
| 2008 | -220.19% | -2078.65% | 0.08x | 1.40x | $-28.32 Million |
| 2009 | -397.46% | -513.77% | 0.49x | 1.59x | $-19.79 Million |
| 2010 | -63.83% | -931.15% | 0.05x | 1.37x | $-6.68 Million |
| 2011 | -24.46% | -1056.56% | 0.02x | 1.24x | $-4.41 Million |
| 2012 | -191.56% | -14383.61% | 0.01x | 1.50x | $-22.23 Million |
| 2013 | -113.25% | -10729.22% | 0.01x | 1.36x | $-33.89 Million |
| 2014 | -35.20% | -33502.97% | 0.00x | 1.10x | $-75.28 Million |
| 2015 | -83.45% | -24068.29% | 0.00x | 1.20x | $-102.96 Million |
| 2016 | -85.50% | -51614.63% | 0.00x | 1.34x | $-91.28 Million |
| 2017 | -42.22% | -109.46% | 0.30x | 1.28x | $-42.52 Million |
| 2018 | -56.84% | -337.32% | 0.14x | 1.17x | $-64.03 Million |
| 2019 | 27.79% | 40.27% | 0.48x | 1.43x | $43.52 Million |
| 2020 | -18.31% | -96.09% | 0.17x | 1.13x | $-130.73 Million |
| 2021 | -34.45% | -101.85% | 0.19x | 1.74x | $-181.73 Million |
| 2022 | -44.29% | -72.56% | 0.35x | 1.74x | $-216.35 Million |
| 2023 | -75.65% | -85.27% | 0.31x | 2.82x | $-232.41 Million |
| 2024 | -323.27% | -16882.37% | 0.00x | 6.15x | $-618.04 Million |
| 2025 | -0.35% | -0.20% | 0.57x | 3.11x | $-48.24 Million |
Industry Comparison
This section compares Arrowhead Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc (ARWR) | $503.42 Million | 0.00% | 1.75x | $9.19 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more